Introduction {#sec1}
============

Spider nevus is a common sign of liver cirrhosis \[[@cit0001]--[@cit0003]\]. Spider nevus is so named because of its spider-like appearance in which there is a central red arteriole and radiating thin-walled vessels resembling the body and legs of a spider, respectively. In the general population, it has been reported that the presence of spider nevus is associated with thyrotoxicosis and excessive estrogen, such as pregnancy and oral contraceptives. In cirrhotic patients, the underlying mechanisms of spider nevus include the disturbance of sex hormones (i.e., higher ratio of estradiol to testosterone, increased level of luteinizing hormone, and decreased level of testosterone in male patients) \[[@cit0004]--[@cit0006]\], angiogenesis (i.e., elevated expression of vascular endothelial growth factor and fibroblast growth factor) \[[@cit0007]\], vasodilation (increased level of substance P) \[[@cit0008]\], alcohol abuse \[[@cit0004]\], hyperdynamic circulation state \[[@cit0009]\], and liver dysfunction \[[@cit0004], [@cit0005]\]. Evidence suggests that spider nevus can predict the grade of liver fibrosis in patients with chronic liver diseases \[[@cit0010]--[@cit0012]\], and is closely associated with the likelihood of hepatopulmonary syndrome in patients with portal hypertension \[[@cit0013], [@cit0014]\].

Subcutaneous collateral vessels of the chest/abdominal wall are also frequently observed in cirrhotic patients \[[@cit0015]\]. In the setting of portal hypertension, paraumbilical vein dilation further leads to the occurrence of subcutaneous collateral vessels of the chest/abdominal wall and even caput medusae \[[@cit0016], [@cit0017]\]. Sometimes, the subcutaneous collateral vessel of the abdominal wall acts as the drainage vessel of intra-abdominal varices, such as stomal and jejunal varices \[[@cit0018], [@cit0019]\]. However, the clinical significance of subcutaneous collateral vessels of the chest/abdominal wall in liver cirrhosis remains unclear.

We conducted a prospective observational study to analyze the impact of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall on the outcomes of patients with liver cirrhosis.

Material and methods {#sec2}
====================

This was a prospective observational study. The study protocol was approved by the Medical Ethical Committee of our hospital. The human study complied with the Declaration of Helsinki. The approval number was No. k(2015)06. The study was also registered in the website clinicaltrial.gov. The register number was NCT02468479. The inclusion criteria were as follows: 1) patients with a diagnosis of liver cirrhosis; and 2) agreement to perform the physical examinations. The exclusion criteria were as follows: 1) a repeated admission; and 2) a confirmed diagnosis of malignancy. The primary endpoint was survival.

Liver cirrhosis was diagnosed based on the clinical symptoms related to liver diseases and portal hypertension, biochemical laboratory tests, liver stiffness measurement, and hepatic ultrasound, computed tomography, and/or magnetic resonance images \[[@cit0020]\]. If necessary, a liver biopsy was performed. Grades of ascites and hepatic encephalopathy were based on the practice guidelines \[[@cit0021], [@cit0022]\]. Management of liver cirrhosis and portal hypertension related complications was based on the current practice guidelines \[[@cit0021]--[@cit0024]\].

At admission, three investigators (RW, YP, and XQ) performed the physical examinations for all eligible patients. In the case of uncertainty, they would discuss it with two primary investigators (HL and XG). According to the number of spider nevi of the chest/abdominal wall, they were divided into 0, 1--2, 3--4, and ≥ 5. According to the location of spider nevi, they were divided into chest wall alone, abdominal wall alone, and both chest and abdominal walls. According to the location of subcutaneous collateral vessels of the chest/abdominal wall, they were divided into chest wall alone, abdominal wall alone, and both chest and abdominal walls. Other baseline data were collected about the demographic profile, major clinical symptoms, etiology of liver cirrhosis, white blood cells, platelet count, hemoglobin, and hepatic, renal, and coagulation function. Child-Pugh and MELD scores were calculated according to the relevant formulae \[[@cit0025], [@cit0026]\].

Patients were followed until lost to follow-up, death, or December 31, 2016. Follow-up data were prospectively collected by two investigators (RW and XQ) from the re-admission records and by telephone contacts.

Statistical analysis {#sec2.1}
--------------------

Statistical analyses were performed using SPSS statistics 17.0.0 and MedCalc 11.4.2.0 software. Continuous data were expressed as the mean ± standard deviation and median (range) and compared using the independent *t* test or non-parametric Mann-Whitney *U* test. Categorical data were expressed as frequency (percentage) and compared using the Pearson χ^2^ test or Fisher's exact test. Cumulative risk was estimated by Kaplan-Meier curve analysis and compared by the log-rank test. A two-sided *p*-value of \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Patients {#sec3.1}
--------

A total of 198 patients were included in the prospective study between June 2015 and May 2016. Patient characteristics are shown in [Table I](#t0001){ref-type="table"}. The majority of patients were male (64.6%), had a history of alcohol abuse (39.9%) and hepatitis B virus infection (32.3%), and were in Child-Pugh class B (51.3%). The in-hospital mortality was 2.02% (4/198). Two patients underwent liver transplantation during follow-up. The overall mortality was 14.14% (28/198) during a mean follow-up duration of 327.5 ±152.97 days (median: 350 days; range: 6--567).

###### 

Baseline characteristics of 198 patients

  Variables                                                          No. pts. with available data   Mean ± SD or Frequency (percentage)   Median (range)
  ------------------------------------------------------------------ ------------------------------ ------------------------------------- -------------------------
  Sex (male/female), *n* (%)                                         198                            128 (64.65)/70 (35.35)                
  Age \[years\]                                                      198                            56.95 ±11.41                          56.38 (26.76--88.10)
  Etiology of liver diseases, *n* (%):                                                                                                    
   Hepatitis B virus infection                                       198                            64 (32.30)                            
   Hepatitis C virus infection                                       198                            18 (9.09)                             
   Alcohol abuse                                                     198                            79 (39.90)                            
   Drug-induced liver injury                                         198                            10 (5.05)                             
   Autoimmune liver disease                                          198                            9 (4.55)                              
  Previous gastrointestinal bleeding, *n* (%)                        198                            106 (53.54)                           
  Hepatic encephalopathy at admission, *n* (%)                       198                            16 (8.08)                             
  Gastrointestinal bleeding at admission, *n* (%)                    198                            106 (53.54)                           
  Jaundice at admission, *n* (%)                                     198                            36 (18.18)                            
  Ascites at admission (no/mild/moderate-severe), *n* (%)            198                            80 (40.40)/39 (19.70)/79 (39.90)      
  Spider nevus of chest/abdominal wall, *n* (%):                     198                            93 (46.97)                            
   Number (1--2/3--4/≥ 5)                                            93                             46 (49.46)/20 (21.51)/27 (29.03)      
   Location (chest alone/abdomen alone/both chest and abdomen)       93                             91 (97.85)/0 (0.00)/2 (2.15)          
  Subcutaneous collateral vessel of chest/abdominal wall, *n* (%):   198                            59 (29.80)                            
   Location (chest alone/abdomen alone/both chest and abdomen)       59                             10 (16.95)/33 (55.93)/16 (27.12)      
  Laboratory tests:                                                                                                                       
   Red blood cells \[× 10^12^/l\]                                    197                            3.14 ±0.83                            3.04 (1.42--5.64)
   Hemoglobin \[g/l\]                                                197                            92.18 ±27.71                          91.00 (37.00--170.00)
   White blood cells \[× 10^9^/l\]                                   197                            5.14 ±3.39                            4.30 (1.10--23.10)
   Platelets \[× 10^9^/l\]                                           197                            91.94 ±59.00                          75.00 (11.00--346.00)
   Alanine aminotransferase \[U/l\]                                  195                            41.62 ±60.47                          25.52 (4.61--590.00)
   Aspartate aminotransferase \[U/l\]                                195                            62.34 ±80.89                          37.66 (6.97--719.84)
   Alkaline phosphatase \[U/l\]                                      195                            126.33 ±105.26                        95.00 (33.00--850.45)
   γ-Glutamyl transpeptidase \[U/l\]                                 195                            115.38 ±176.31                        46.16 (9.00--981.00)
   Total bilirubin \[µmol/l\]                                        195                            37.06 ±46.01                          23.40 (6.40--319.90)
   Prothrombin time \[s\]                                            193                            16.55 ±3.31                           15.70 (11.30--31.60)
   International normalized ratio                                    191                            1.38 ±0.38                            1.29 (0.83--3.03)
   Activated partial thromboplastin time \[s\]                       192                            40.54 ±5.99                           39.65 (29.20--57.80)
   Albumin \[g/l\]                                                   194                            30.35 ±6.84                           29.70 (16.10--48.10)
   Serum sodium \[mmol/l\]                                           196                            138.85 ±3.91                          138.40 (120.70--151.60)
   Serum potassium \[mmol/l\]                                        196                            3.91 ±0.46                            3.87 (2.48--5.60)
   Blood urea nitrogen \[mmol/l\]                                    194                            7.57 ±5.88                            5.72 (1.71--47.21)
   Serum creatinine \[µmol/l\]                                       194                            78.44 ±65.04                          65.41 (32.14--533.70)
  Child-Pugh score                                                   189                            7.89 ±2.09                            8.00 (5.00--14.00)
  Child-Pugh class A/B/C, *n* (%)                                    189                            55 (29.10)/97 (51.32)/37 (19.58)      
  MELD score                                                         187                            8.64 ±6.02                            7.70 (--2.38--28.02)
  In-hospital death, *n* (%)                                         198                            4 (2.02)                              
  Overall death, *n* (%)                                             198                            28 (14.14)                            

SD -- standard deviation, MELD -- model for end-stage liver disease.

Spider nevus of chest/abdominal wall {#sec3.2}
------------------------------------

The prevalence of spider nevus of the chest/abdominal wall was 47% (93/198). Of the 93 patients with spider nevi, 49.46% (46/93), 21.51% (20/93), and 29.03% (27/93) had 1--2, 3--4, and ≥ 5 spider nevi, respectively. The location of the spider nevus was the chest wall alone in nearly all patients (97.85%, 91/93).

Patients with spider nevi of the chest/abdominal wall had significantly higher proportions of male sex, alcohol abuse, subcutaneous collateral vessel of the chest/abdominal wall, and Child-Pugh classes B and C, significantly higher hemoglobin, white blood cells, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, activated partial thromboplastin time, Child-Pugh score, and MELD score, and significantly lower sodium, and were significantly younger than those without spider nevi of the chest/abdominal wall ([Table II](#t0002){ref-type="table"}). The cumulative survival was not significantly different between patients with and without spider nevi of the chest/abdominal wall (*p* = 0.951) ([Figure 1 A](#f0001){ref-type="fig"}).

###### 

Comparison between patients with and without spider nevus of chest/abdominal wall

  Variables                                                          With spider nevus of chest/abdominal wall   Without spider nevus of chest/abdominal wall   *P*-value                                                                                    
  ------------------------------------------------------------------ ------------------------------------------- ---------------------------------------------- ------------------------- ----- ---------------------------------- ------------------------- ----------
  Sex (male/female), *n* (%)                                         93                                          68 (73.12)/25 (26.88)                                                    105   60 (57.14)/45 (42.86)                                        0.028
  Age (years\]                                                       93                                          54.19 ±10.03                                   53.83 (27.08--82.34)      105   59.39 ±12.03                       59.89 (26.76--88.10)      0.001
  Etiology of liver diseases, *n* (%):                                                                                                                                                                                                                       
   Hepatitis B virus infection                                       93                                          25 (26.88)                                                               105   39 (37.14)                                                   0.104
   Hepatitis C virus infection                                       93                                          5 (5.38)                                                                 105   13 (12.38)                                                   0.099
   Alcohol abuse                                                     93                                          51 (54.84)                                                               105   28 (26.67)                                                   \< 0.001
   Drug-induced liver injury                                         93                                          3 (3.23)                                                                 105   7 (6.67)                                                     0.436
   Autoimmune liver disease                                          93                                          4 (4.30)                                                                 105   5 (4.76)                                                     0.852
  Previous gastrointestinal bleeding, *n* (%)                        93                                          42 (45.16)                                                               105   64 (60.95)                                                   0.038
  Hepatic encephalopathy at admission, *n* (%)                       93                                          43 (46.24)                                                               105   63 (60.00)                                                   0.073
  Gastrointestinal bleeding at admission, *n* (%)                    93                                          20 (21.51)                                                               105   16 (15.24)                                                   0.339
  Jaundice at admission, *n* (%)                                     93                                          2 (2.15)                                                                 105   2 (1.90)                                                     0.701
  Ascites at admission (no/mild/moderate-severe), *n* (%)            93                                          31 (33.33)/17 (18.28)/45 (48.39)                                         105   49 (46.67)/22 (20.95)/34 (32.38)                             0.063
  Subcutaneous collateral vessel of chest/abdominal wall, *n* (%):   93                                          35 (37.63)/58 (62.37)                                                    105   24 (22.86)/81 (77.14)                                        0.035
   Location (chest alone/abdomen alone/both chest and abdomen)       35                                          5 (14.29)/17 (48.57)/13 (37.14)                                          24    5 (20.83)/16 (66.67)/3 (12.50)                               0.112
  Laboratory tests:                                                                                                                                                                                                                                          
   Red blood cells \[× 10^12^/l\]                                    93                                          3.20 ±0.83                                     3.11 (1.69--5.06)         104   3.09 ±0.83                         2.97 (1.42--5.64)         0.356
   Hemoglobin \[g/l\]                                                93                                          97.60 ±27.95                                   96.00 (47.00--170.00)     104   87.33 ±26.71                       83.00 (37.00--164.00)     0.012
   White blood cells \[× 10^9^/l\]                                   93                                          5.27 ±2.82                                     4.50 (1.70--16.00)        103   5.04 ±3.86                         4.00 (1.10--23.10)        0.047
   Platelets \[× 10^9^/l\]                                           93                                          95.55 ±57.36                                   81.00 (19.00--282.00)     104   88.71 ±60.53                       73.50 (11.00--346.00)     0.316
   Alanine aminotransferase \[U/l\]                                  92                                          48.64 ±77.82                                   28.50 (6.24--590.00)      103   35.36 ±38.32                       22.07 (4.61--192.51)      0.005
   Aspartate aminotransferase \[U/l\]                                92                                          77.72 ±101.85                                  47.07 (13.54--719.84)     103   48.60 ±52.79                       31.20 (6.97--300.70)      \< 0.001
   Alkaline phosphatase \[U/l\]                                      92                                          131.27 ±95.28                                  101.74 (33.00--649.21)    103   121.91 ±113.72                     85.59 (35.36--850.45)     0.049
   γ-Glutamyl transpeptidase \[U/l\]                                 92                                          153.41 ±204.87                                 73.60 (9.00--981.00)      103   81.41 ±138.59                      34.65 (9.67--797.00)      \< 0.001
   Total bilirubin \[µmol/l\]                                        92                                          48.13 ±59.90                                   28.95 (6.40--319.90)      103   27.18 ±24.81                       20.10 (7.10--179.20)      0.004
   Prothrombin time \[s\]                                            93                                          16.97 ±3.54                                    15.90 (11.70--31.60)      100   16.15 ±3.06                        15.55 (11.30--29.70)      0.080
   International normalized ratio                                    92                                          1.43 ±0.40                                     1.31 (0.89--3.03)         99    1.34 ±0.35                         1.25 (0.83--3.00)         0.065
   Activated partial thromboplastin time \[s\]                       93                                          41.43 ±6.08                                    40.30 (29.40--54.50)      99    39.71 ±5.81                        38.60 (29.20--57.80)      0.040
   Albumin \[g/l\]                                                   92                                          29.84 ±6.91                                    29.40 (16.10--47.20)      102   30.80 ±6.78                        30.20 (17.20--48.10)      0.404
   Serum sodium \[mmol/l\]                                           92                                          136.67 ±4.18                                   137.50 (120.70--144.60)   104   138.89 ±3.34                       139.40 (130.40--151.60)   \< 0.001
   Serum potassium \[mmol/l\]                                        92                                          3.90 ±0.45                                     3.85 (2.73--4.88)         104   3.92 ±0.47                         3.87 (2.48--5.60)         0.987
   Blood urea nitrogen \[mmol/l\]                                    93                                          7.43 ±6.59                                     5.50 (1.90--47.21)        101   7.69 ±5.16                         6.03 (1.71--30.40)        0.134
   Serum creatinine \[µmol/l\]                                       93                                          81.90 ±72.93                                   65.69 (32.14--533.70)     101   75.25 ±57.00                       65.30 (34.90--440.06)     0.651
  Child-Pugh score                                                   91                                          8.35 ±2.19                                     8.00 (5.00--14.00)        98    7.47 ±1.91                         7.00 (5.00--13.00)        0.005
  Child-Pugh class A/B/C, *n* (%)                                    91                                          17 (18.68)/50 (54.95)/24 (26.37)                                         98    38 (38.78)/47 (47.96)/13 (13.26)                             0.004
  MELD score                                                         91                                          9.91 ±6.41                                     8.86 (--1.42 -- 28.02)    96    7.43 ±5.40                         5.66 (--2.38 -- 22.05)    0.008
  In-hospital death, *n* (%)                                         93                                          2 (2.15)                                                                 105   2 (1.90)                                                     0.701
  Overall death, *n* (%)                                             93                                          13 (13.98)                                                               105   15 (14.29)                                                   0.887

SD -- standard deviation, MELD -- model for end-stage liver disease.

![Kaplan-Meir curve regarding the impact of spider nevus on cumulative survival of cirrhotic patients. **A** -- Patients with vs. without spider nevus. **B** -- Patients with 1--2 vs. 3--4 vs. ≥ 5 spider nevi of chest/abdominal wall](AMS-15-32432-g001){#f0001}

Proportions of male sex and alcohol abuse were significantly different among patients with different numbers of spider nevi of the chest/abdominal wall ([Table III](#t0003){ref-type="table"}). The cumulative survival was not significantly different among them (*p* = 0.151) ([Figure 1 B](#f0001){ref-type="fig"}).

###### 

Comparison among patients with different number of spider nevi

  Variables                                                          With 1--2 spider nevi of chest/abdominal wall   With 3--4 spider nevi of chest/abdominal wall   With ≥ 5 spider nevi of chest/abdominal wall   *P*-value                                                                                                                               
  ------------------------------------------------------------------ ----------------------------------------------- ----------------------------------------------- ---------------------------------------------- ----------- -------------------------------- ------------------------- ---- --------------------------------- ------------------------- -------
  Sex (male/female), *n* (%)                                         46                                              28 (60.87)/18 (39.13)                                                                          20          15 (75.00)/5 (25.00)                                       27   25 (92.59)/2 (7.41)                                         0.013
  Age \[years\]                                                      46                                              56.43 ±11.52                                    56.62 (27.08--82.34)                           20          52.48 ±7.91                      53.28 (32.45--66.89)      27   51.63 ±7.93                       35.71 (35.74--69.03)      0.098
  Etiology of liver diseases, *n* (%):                                                                                                                                                                                                                                                     27                                                               
   Hepatitis B virus infection                                       46                                              13 (28.26)                                                                                     20          7 (35.00)                                                  27   5 (18.52)                                                   0.125
   Hepatitis C virus infection                                       46                                              4 (8.70)                                                                                       20          1 (5.00)                                                   27   0 (0.00)                                                    0.371
   Alcohol abuse                                                     46                                              19 (41.30)                                                                                     20          10 (50.00)                                                 27   22 (81.48)                                                  0.004
   Drug-induced liver injury                                         46                                              2 (4.35)                                                                                       20          0 (0.00)                                                   27   1 (3.70)                                                    0.647
   Autoimmune liver disease                                          46                                              2 (4.35)                                                                                       20          2 (10.00)                                                  27   0 (0.00)                                                    0.248
  Previous gastrointestinal bleeding, *n* (%)                        46                                              22 (47.83)                                                                                     20          8 (40.00)                                                  27   12 (44.44)                                                  0.838
  Hepatic encephalopathy at admission, *n* (%)                       46                                              5 (10.87)                                                                                      20          2 (10.00)                                                  27   4 (14.81)                                                   0.846
  Gastrointestinal bleeding at admission, *n* (%)                    46                                              24 (52.17)                                                                                     20          9 (45.00)                                                  27   10 (37.04)                                                  0.453
  Jaundice at admission, *n* (%)                                     46                                              10 (21.74)                                                                                     20          3 (15.00)                                                  27   7 (25.93)                                                   0.665
  Ascites at admission (no/mild/moderate-severe), *n* (%)            46                                              15 (32.61)/7 (15.22)/24 (52.17)                                                                20          6 (30.00)/4 (20.00)/10 (50.00)                             27   10 (37.03)/6 (22.22)/11 (40.74)                             0.885
  Subcutaneous collateral vessel of chest/abdominal wall, *n* (%):   46                                              13 (28.26)/33 (71.74)                                                                          20          10 (50.00)/10 (50.00)                                      27   12 (44.44)/15 (55.56)                                       0.169
   Location (chest alone/abdomen alone/both chest and abdomen)       13                                              0 (0.00)/7 (53.85)/6 (46.15)                                                                   10          2 (20.00)/4 (40.00)/4 (40.00)                              12   3 (25.00)/6 (50.00)/3 (25.00)                               0.398
  Laboratory tests:                                                                                                                                                                                                                                                                                                                                         
   Red blood cells \[× 10^12^/l\]                                    46                                              3.18 ±0.86                                      3.05 (1.69--5.06)                              20          3.32 ±0.81                       3.18 (2.09--4.81)         27   3.15 ±0.80                        3.13 (1.74--5.02)         0.755
   Hemoglobin \[g/l\]                                                46                                              91.91 ±26.75                                    83.50 (54.00--149.00)                          20          102.80 ±32.74                    100.00 (47.00--151.00)    27   103.44 ±25.08                     101.00 (52.00--170.00)    0.152
   White blood cells \[× 10^9^/l\]                                   46                                              5.54 ±3.15                                      4.45 (1.70--14.50)                             20          4.78 ±1.28                       4.70 (2.30--6.70)         27   5.18 ±3.06                        4.30 (1.80--16.00)        0.588
   Platelets \[× 10^9^/l\]                                           46                                              93.67 ±56.56                                    74.00 (29.00--282.00)                          20          112.40 ±67.45                    95.50 (36.00--282.00)     27   86.26 ±49.67                      84.00 (19.00--192.00)     0.290
   Alanine aminotransferase \[U/l\]                                  45                                              46.16 ±70.77                                    25.85 (13.42--466.75)                          20          61.61 ±125.73                    29.87 (6.24--590.00)      27   43.15 ±31.60                      41.89 (12.54--170.79)     0.697
   Aspartate aminotransferase \[U/l\]                                45                                              72.22 ±108.88                                   39.85 (18.16--719.84)                          20          82.24 ±136.02                    47.47 (13.54--645.00)     27   83.53 ±51.22                      72.00 (15.35--166.49)     0.881
   Alkaline phosphatase \[U/l\]                                      45                                              121.17 ±107.03                                  94.64 (39.17--649.21)                          20          145.25 ±98.69                    116.00 (47.00--444.88)    27   137.75 ±69.28                     118.46 (33.00--386.00)    0.593
   Gamma-glutamyl transpeptidase \[U/l\]                             45                                              117.82 ±191.67                                  60.66 (9.00--929.28)                           20          191.77 ±266.82                   67.74 (10.00--981.00)     27   184.33 ±168.48                    94.00 (12.18--552.26)     0.265
   Total bilirubin \[µmol/l\]                                        45                                              47.24 ±59.91                                    26.00 (7.70--316.90)                           20          35.63 ±30.14                     27.55 (8.80--138.00)      27   58.86 ±74.70                      37.50 (6.40--319.90)      0.422
   Prothrombin time \[s\]                                            46                                              17.07 ±3.82                                     15.85 (11.70--31.60)                           20          16.40 ±3.52                      15.80 (12.30--28.90)      27   17.23 ±3.10                       15.90 (13.00--25.20)      0.703
   International normalized ratio                                    45                                              1.44 ±0.43                                      1.30 (0.89--3.03)                              20          1.37 ±0.41                       1.28 (0.93--2.89)         27   1.45 ±0.35                        1.31 (0.97--2.36)         0.720
   Activated partial thromboplastin time \[s\]                       46                                              40.90 ±6.33                                     40.30 (29.40--54.50)                           20          40.16 ±5.15                      38.50 (32.70--52.80)      27   43.29 ±6.07                       43.10 (34.30--54.50)      0.154
   Albumin \[g/l\]                                                   46                                              29.72 ±7.03                                     29.15 (17.80--47.20)                           19          31.22 ±5.86                      30.10 (19.80--42.40)      27   29.10 ±7.48                       29.30 (16.10--43.40)      0.587
   Serum sodium \[mmol/l\]                                           46                                              137.05 ±3.57                                    137.20 (129.80--144.60)                        19          137.54 ±3.86                     138.40 (128.00--143.40)   27   135.43 ±5.13                      137.50 (120.70--141.20)   0.168
   Serum potassium \[mmol/l\]                                        46                                              3.90 ±0.41                                      3.88 (3.01--4.85)                              19          3.89 ±0.48                       3.81 (2.73--4.66)         27   3.91 ±0.50                        3.94 (2.96--4.88)         0.990
   Blood urea nitrogen \[mmol/l\]                                    46                                              7.85 ±5.67                                      6.13 (2.45--32.70)                             20          6.37 ±4.75                       5.24 (2.24--25.59)        27   7.50 ±8.96                        4.86 (1.90--47.21)        0.710
   Serum creatinine \[µmol/l\]                                       45                                              75.74 ±48.06                                    64.55 (32.14--317.30)                          20          89.17 ±89.74                     70.19 (44.00--463.47)     27   87.01 ±93.83                      64.20 (41.76--533.70)     0.723
  Child-Pugh score                                                   45                                              8.40 ±2.26                                      8.00 (5.00--14.00)                             19          8.05 ±1.47                       8.00 (5.00--10.00)        27   8.48 ±2.53                        8.00 (5.00--13.00)        0.794
  Child-Pugh class A/B/C, *n* (%)                                    45                                              8 (17.78)/26 (57.78)/11 (24.44)                                                                19          2 (10.53)/14 (73.68)/3 (15.79)                             27   7 (25.92)/10 (37.04)/10 (37.04)                             0.175
  MELD score                                                         44                                              9.52 ±6.44                                      8.89 (--1.42--22.78)                           20          9.41 ±6.41                       8.15 (0.41--28.02)        27   10.92 ±6.47                       9.16 (--1.15 -- 23.47)    0.624
  In-hospital death, *n* (%)                                         46                                              1 (2.17)                                                                                       20          0 (0.00)                                                   27   1 (3.70)                                                    0.688
  Overall death, *n* (%)                                             46                                              9 (19.57)                                                                                      20          2 (10.00)                                                  27   2 (7.41)                                                    0.297

SD -- standard deviation, MELD -- model for end-stage liver disease.

Subcutaneous collateral vessel of chest/abdominal wall {#sec3.3}
------------------------------------------------------

The prevalence of subcutaneous collateral vessel of the chest/abdominal wall was 29.8% (59/198). The location of the subcutaneous collateral vessel was the chest wall alone, the abdominal wall alone, and both chest and abdominal walls in 16.9% (10/59), 55.9% (33/59), and 27.1% (16/59), respectively.

Patients with subcutaneous collateral vessels of the chest/abdominal wall had significantly higher proportions of moderate to severe ascites at admission, spider nevus, and Child-Pugh class C, significantly higher alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase, total bilirubin, Child-Pugh score, and MELD score, significantly lower proportions of previous history of gastrointestinal bleeding and gastrointestinal bleeding at admission, and significantly lower sodium than those without subcutaneous collateral vessel of chest/abdominal wall ([Table IV](#t0004){ref-type="table"}). The cumulative survival was significantly worse in patients with a subcutaneous collateral vessel of the chest/abdominal wall than in those without a subcutaneous collateral vessel of the chest/abdominal wall (*p* = 0.018) ([Figure 2 A](#f0002){ref-type="fig"}).

###### 

Comparison between patients with and without subcutaneous collateral vessel of chest/abdominal wall

  Variables                                                      With subcutaneous collateral vessel of chest/abdominal wall   Without subcutaneous collateral vessel of chest/abdominal wall   *P*-value                                                                                    
  -------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- ------------------------- ----- ---------------------------------- ------------------------- ----------
  Sex (male/female), *n* (%)                                     59                                                            37 (62.71)/22 (37.29)                                                                      139   91 (65.47)/48 (34.53)                                        0.835
  Age \[years\]                                                  59                                                            57.19 ±11.75                                                     57.01 (31.96--88.10)      139   56.84 ±11.30                       56.31 (26.76--82.34)      0.713
  Etiology of liver diseases, *n* (%):                                                                                                                                                                                                                                                       
   Hepatitis B virus infection                                   59                                                            18 (30.51)                                                                                 139   46 (33.09)                                                   0.850
   Hepatitis C virus infection                                   59                                                            3 (5.08)                                                                                   139   15 (10.79)                                                   0.314
   Alcohol abuse                                                 59                                                            28 (47.46)                                                                                 139   51 (36.69)                                                   0.209
   Drug-induced liver injury                                     59                                                            1 (1.69)                                                                                   139   9 (6.47)                                                     0.294
   Autoimmune liver disease                                      59                                                            2 (3.39)                                                                                   139   7 (5.04)                                                     0.892
  Previous gastrointestinal bleeding, *n* (%)                    59                                                            24 (40.68)                                                                                 139   82 (58.99)                                                   0.027
  Hepatic encephalopathy at admission, *n* (%)                   59                                                            4 (6.78)                                                                                   139   12 (8.63)                                                    0.879
  Gastrointestinal bleeding at admission, *n* (%)                59                                                            19 (32.20)                                                                                 139   87 (62.59)                                                   \< 0.001
  Jaundice at admission, *n* (%)                                 59                                                            16 (27.12)                                                                                 139   20 (14.39)                                                   0.055
  Ascites at admission (no/mild/moderate-severe), *n* (%)        59                                                            15 (25.42)/9 (15.25)/35 (59.32)                                                            139   65 (46.76)/30 (21.58)/44 (31.65)                             0.001
  Spider nevus of chest/abdominal wall, *n* (%):                 59                                                            35 (59.32)                                                                                 139   58 (41.73)                                                   0.035
   Number (1--2/3--4/≥ 5)                                        35                                                            13 (37.14)/10 (28.57)/12 (34.29)                                                           58    33 (56.90)/10 (17.24)/15 (25.86)                             0.169
   Location (chest alone/abdomen alone/both chest and abdomen)   35                                                            34 (97.14)/0 (0)/1 (2.86)                                                                  58    57 (98.28)/0 (0.00)/1 (1.02)                                 0.071
  Laboratory tests:                                                                                                                                                                                                                                                                          
   Red blood cells \[× 10^12^/l\]                                59                                                            3.14 ±0.78                                                       3.06 (1.42--5.02)         138   3.15 ±0.85                         3.04 (1.43--5.64)         0.839
   Hemoglobin \[g/l\]                                            59                                                            93.92 ±26.08                                                     95.00 (38.00--170.00)     138   91.44 ±28.45                       84.00 (37.00--164.00)     0.455
   White blood cells \[× 10^9^/l\]                               59                                                            5.16 ±3.26                                                       4.40 (1.40--16.00)        138   5.13 ±3.46                         4.30 (1.10--23.10)        0.810
   Platelets \[× 10^9^/l\]                                       59                                                            97.02 ±61.34                                                     83.00 (11.00--282.00)     138   89.77 ±58.07                       74.00 (17.00--346.00)     0.439
   Alanine aminotransferase \[U/l\]                              59                                                            42.98 ±37.79                                                     30.22 (6.24--192.51)      136   41.04 ±68.12                       24.41 (4.61--590.00)      0.046
   Aspartate aminotransferase \[U/l\]                            59                                                            70.23 ±56.98                                                     52.42 (13.54--300.70)     136   58.91 ±89.27                       33.27 (6.97--719.84)      0.003
   Alkaline phosphatase \[U/l\]                                  59                                                            161.57 ±131.87                                                   124.79 (33.00--850.45)    136   111.04 ±87.59                      86.82 (35.36--649.21)     0.003
   γ-Glutamyl transpeptidase \[U/l\]                             59                                                            137.47 ±175.01                                                   74.58 (10.00--929.28)     136   105.80 ±176.65                     41.26 (9.00--981.00)      0.009
   Total bilirubin \[µmol/l\]                                    59                                                            53.34 ±64.62                                                     29.20 (7.90--319.90)      136   30.00 ±32.89                       22.20 (6.40--316.90)      0.009
   Prothrombin time \[s\]                                        59                                                            17.06 ±3.61                                                      15.70 (12.50--29.70)      135   16.33 ±3.17                        15.70 (11.30--31.60)      0.318
   International normalized ratio                                58                                                            1.44 ±0.41                                                       1.29 (0.95--3.00)         133   1.36 ±0.36                         1.28 (0.83--3.03)         0.258
   Activated partial thromboplastin time \[s\]                   58                                                            42.47 ±6.12                                                      41.15 (29.50--56.10)      134   39.71 ±5.76                        38.50 (29.20--57.80)      0.004
   Albumin \[g/l\]                                               59                                                            29.89 ±6.29                                                      29.20 (17.20--47.80)      135   30.55 ±7.08                        30.10 (16.10--481.00)     0.557
   Serum sodium \[mmol/l\]                                       58                                                            136.36 ±4.71                                                     137.50 (120.70--143.00)   138   138.48 ±3.35                       138.50 (128.00--151.60)   0.019
   Serum potassium \[mmol/l\]                                    58                                                            3.89 ±0.48                                                       3.88 (2.73--4.88)         138   3.92 ±0.45                         3.87 (2.48--5.60)         0.808
   Blood urea nitrogen \[mmol/l\]                                59                                                            7.90 ±6.61                                                       5.62 (2.24--32.70)        135   7.42 ±5.54                         5.82 (1.71--47.21)        0.858
   Serum creatinine \[µmol/l\]                                   59                                                            87.89 ±77.69                                                     65.81 (32.14--463.47)     135   74.31 ±58.52                       64.42 (34.90--533.70)     0.192
  Child-Pugh score                                               58                                                            8.57 ±2.20                                                       8.00 (5.00--14.00)        131   7.60 ±1.98                         7.00 (5.00--14.00)        0.002
  Child-Pugh class A/B/C, *n* (%)                                58                                                            11 (18.97)/29 (50)/18 (31.03)                                                              131   44 (33.59)/68 (51.91)/19 (14.50)                             0.014
  MELD score                                                     58                                                            10.77 ±6.76                                                      9.16 (--1.42--28.02)      129   7.68 ±5.42                         6.16 (--2.38 -- 23.47)    0.003
  In-hospital death, *n* (%)                                     59                                                            1 (1.69)                                                                                   139   3 (2.16)                                                     0.734
  Overall death, *n* (%)                                         59                                                            13 (22.03)                                                                                 139   13 (9.35)                                                    0.022

SD -- standard deviation, MELD -- model for end-stage liver disease.

![Kaplan-Meir curve regarding the impact of subcutaneous collateral vessel of abdominal/chest wall on cumulative survival of cirrhotic patients. **A** -- Patients with versus without subcutaneous collateral vessel of abdominal/chest wall. **B** -- Patients with subcutaneous collateral vessel of chest wall alone versus abdominal wall alone versus both abdominal and chest walls](AMS-15-32432-g002){#f0002}

Age, proportion of alcohol abuse, white blood cells, platelets, and gamma-glutamyl transpeptidase were significantly different among patients with different locations of the subcutaneous collateral vessel ([Table V](#t0005){ref-type="table"}). The cumulative survival was not significantly different among them (*p* = 0.532) ([Figure 2 B](#f0002){ref-type="fig"}).

###### 

Comparison among patients with different location of subcutaneous collateral vessel of chest/abdominal wall

  Variables                                                      Chest wall alone   Abdominal wall alone            Both                      *P*-value                                                                                                                             
  -------------------------------------------------------------- ------------------ ------------------------------- ------------------------- ----------- --------------------------------- ------------------------- ---- ------------------------------- ------------------------ -------
  Sex (male/female), *n* (%)                                     10                 5 (50.00)/5 (50.00)                                       33          18 (54.55)/15 (45.45)                                       16   14 (87.50)/2 (12.50)                                     0.054
  Age \[years\]                                                  10                 61.01 ±15.01                    57.54 (45.17--88.10)      33          59.15 ±11.69                      62.23 (31.96--78.67)      16   50.77 ±6.70                     51.31 (39.61--62.71)     0.034
  Etiology of liver diseases, *n* (%):                                                                                                                                                                                                                                              
   Hepatitis B virus infection                                   10                 3 (30.00)                                                 33          14 (42.42)                                                  16   1 (6.25)                                                 0.099
   Hepatitis C virus infection                                   10                 0 (0.00)                                                  33          1 (3.03)                                                    16   2 (12.50)                                                0.266
   Alcohol abuse                                                 10                 3 (30.00)                                                 33          12 (36.36)                                                  16   13 (81.25)                                               0.006
   Drug-induced liver injury                                     10                 0 (0.00)                                                  33          1 (3.03)                                                    16   0 (0.00)                                                 0.670
   Autoimmune liver disease                                      10                 0 (0.00)                                                  33          2 (6.06)                                                    16   0 (0.00)                                                 0.442
  Previous gastrointestinal bleeding, *n* (%)                    10                 6 (60.00)                                                 33          13 (39.39)                                                  16   5 (31.25)                                                0.340
  Hepatic encephalopathy at admission, *n* (%)                   10                 0 (0.00)                                                  33          2 (6.06)                                                    16   2 (12.50)                                                0.453
  Gastrointestinal bleeding at admission, *n* (%)                10                 4 (40.00)                                                 33          7 (21.21)                                                   16   8 (50.00)                                                0.109
  Jaundice at admission, *n* (%)                                 10                 2 (20.00)                                                 33          8 (24.24)                                                   16   6 (37.50)                                                0.531
  Ascites at admission (no/mild/moderate-severe), *n* (%)        10                 4 (40.00)/3 (30.00)/3 (30.00)                             33          8 (24.24)/5 (15.15)/20 (60.61)                              16   3 (18.75)/1 (6.25)/12 (75.00)                            0.237
  Spider nevus of chest/abdominal wall, *n* (%):                 10                 5 (50.00)                                                 33          17 (51.52)                                                  16   13 (81.25)                                               0.112
   Number (1--2/3--4/≥ 5)                                        5                  0 (0.00)/2 (40.00)/3 (60.00)                              17          7 (41.18)/4 (23.53)/6 (35.29)                               13   6 (46.15)/4 (30.77)/3 (23.08)                            0.398
   Location (chest alone/abdomen alone/both chest and abdomen)   10                 5 (50.00)/5 (50.00)/0 (0.00)                              33          16 (48.48)/16 (48.48)/1 (3.03)                              16   3 (18.75)/13 (81.25)/0 (0.00)                            0.238
  Laboratory tests:                                                                                                                                                                                                                                                                 
   Red blood cells \[10^12^/l\]                                  10                 3.35 ±0.99                      3.42 (1.42--4.89)         33          3.27 ±0.76                        3.11 (2.09--5.02)         16   2.75 ±0.58                      2.73 (1.69--3.91)        0.093
   Hemoglobin \[g/l\]                                            10                 97.10 ±29.35                    100.50 (38.00--131.00)    33          97.91 ±25.75                      95.00 (55.00--170.00)     16   83.69 ±23.25                    84.5 (47.00--128.00)     0.185
   White blood cells \[× 10^9^/l\]                               10                 3.42 ±1.26                      3.40 (1.40--5.30)         33          4.63 ±2.57                        4.20 (1.70--14.00)        16   7.34 ±4.28                      5.75 (2.90--16.00)       0.003
   Platelets \[× 10^9^/l\]                                       10                 90.20 ±59.44                    71.50 (34.00--228.00)     33          82.24 ±42.91                      73.00 (11.00--171.00)     16   131.75 ±81.88                   116.5 (22.00--282.00)    0.025
   Alanine aminotransferase \[U/l\]                              10                 51.33 ±45.86                    44.26 (11.77--164.25)     33          45.40 ±42.13                      30.22 (6.24--192.51)      16   32.78 ±17.41                    27.57 (13.42--73.00)     0.416
   Aspartate aminotransferase \[U/l\]                            10                 76.34 ±59.34                    64.72 (15.85--211.18)     33          66.99 ±61.31                      48.46 (13.54--300.70)     16   73.11 ±48.67                    64.78 (19.64--161.31)    0.846
   Alkaline phosphatase \[U/l\]                                  10                 210.63 ±164.21                  142.37 (49.82--542.00)    33          156.70 ±145.44                    114.00 (33.00--850.45)    16   140.94 ±61.83                   136.5 (45.00--282.00)    0.410
   γ-Glutamyl transpeptidase \[U/l\]                             10                 120.78 ±115.29                  89.85 (19.22--399.94)     33          92.31 ±92.99                      47.00 (10.00--349.83)     16   241.04 ±275.49                  122 (11.00--929.28)      0.017
   Total bilirubin \[µmol/l\]                                    10                 34.91 ±27.13                    33.85 (7.90--97.30)       33          52.94 ±64.98                      24.40 (8.00--281.70)      16   65.68 ±79.42                    41.6 (10.50--319.90)     0.432
   Prothrombin time \[s\]                                        10                 16.91 ±3.40                     15.60 (13.40--25.20)      33          17.01 ±3.90                       15.70 (12.50--29.70)      15   17.26 ±3.27                     15.5 (12.80--22.50)      0.967
   International normalized ratio                                10                 1.42 ±0.38                      1.28 (1.04--2.36)         33          1.44 ±0.45                        1.29 (0.95--3.00)         15   1.47 ±0.37                      1.26 (0.98--2.07)        0.965
   Activated partial thromboplastin time \[s\]                   10                 43.67 ±7.35                     42.60 (34.80--54.50)      33          42.07 ±6.41                       40.30 (29.50--56.10)      16   42.57 ±4.72                     42.9 (34.00--51.00)      0.773
   Albumin \[g/l\]                                               10                 31.08 ±8.13                     31.05 (17.20--41.70)      33          30.82 ±6.51                       31.00 (18.90--47.80)      16   27.21 ±3.49                     28.9 (19.90--31.00)      0.136
   Serum sodium \[mmol/l\]                                       10                 138.08 ±3.59                    139.85 (131.90--141.20)   33          136.77 ±4.73                      138.40 (120.70--142.10)   15   134.29 ±4.86                    134.7 (123.20--143.00)   0.105
   Serum potassium \[mmol/l\]                                    10                 3.82 ±0.52                      3.77 (2.90--4.44)         33          3.88 ±0.45                        3.88 (2.73--4.66)         15   3.95 ±0.54                      3.84 (3.01--4.88)        0.789
   Blood urea nitrogen \[mmol/l\]                                10                 6.46 ±3.52                      5.10 (4.18--15.89)        33          8.03 ±7.05                        5.58 (2.35--30.40)        16   8.55 ±7.34                      7.16 (2.24--32.70)       0.733
   Serum creatinine \[µmol/l\]                                   10                 83.97 ±47.27                    69.20 (50.29--212.26)     33          91.46 ±96.47                      65.30 (35.05--463.47)     16   82.96 ±45.59                    72.75 (32.14--193.66)    0.926
  Child-Pugh score                                               10                 7.80±1.99                       8.00 (5.00--11.00)        33          8.39 ±2.37                        8.00 (5.00--13.00)        15   9.47 ±1.73                      9.00 (8.00--14.00)       0.141
  Child-Pugh class A/B/C, *n* (%)                                10                 4 (40.00)/4 (40.00)/2 (20.00)                             33          7 (21.21)/16 (48.49)/10 (30.30)                             15   0 (0.00)/9 (60.00)/6 (40.00)                             0.161
  MELD score                                                     10                 10.06 ±3.84                     8.78 (5.63--18.35)        33          10.33 ±7.95                       7.66 (--1.42--28.02)      15   12.22 ±5.38                     12.77 (0.62--20.41)      0.633
  In-hospital death, *n* (%)                                     10                 0 (0.00)                                                  33          0 (0.00)                                                    16   1 (6.25)                                                 0.255
  Overall death, *n* (%)                                         10                 1 (10.00)                                                 33          8 (24.24)                                                   16   5 (31.25)                                                0.462

SD -- standard deviation, MELD -- model for end-stage liver disease.

Discussion {#sec4}
==========

The patients enrolled in our study had several major features. First, our patients formed a group of the northeastern Chinese population with liver cirrhosis. In northeastern China, the most common etiologies of liver cirrhosis are alcohol abuse and hepatitis B virus infection \[[@cit0027]\]. Indeed, one third of our patients had a history of alcohol abuse and another one third of them had hepatitis B virus infection. Second, a majority of our patients were at the decompensation status, because approximately half of them had developed gastrointestinal bleeding and about two thirds of them had ascites at their admission. Third, most of our patients had relatively severe liver dysfunction, because about two thirds of them were in Child-Pugh class B or C at their admission.

The characteristics of spider nevi and subcutaneous collateral vessels should be interpreted as follows. First, about half of cirrhotic patients had spider nevi of the chest/abdominal wall. Notably, nearly all spider nevi occurred at the chest wall; by comparison, spider nevus was hardly observed at the abdominal wall. Therefore, no comparison was performed according to the location of the spider nevus. Second, about one third of cirrhotic patients had subcutaneous collateral vessels of the chest/abdominal wall. Notably, a majority of them occurred at the abdominal walls.

In line with previous findings by Li *et al.* \[[@cit0004]\], our study also confirmed that alcohol abuse was significantly associated with the presence of spider nevus. More importantly, the proportion of subjects with a history of alcohol abuse increased with the number of spider nevi. Considering that alcohol abuse is more common in male patients, we can further explain the association of sex with spider nevus of the chest/abdominal wall. By contrast, the potential etiology of chronic liver diseases did not influence the development of a subcutaneous collateral vessel of the chest/abdominal wall.

Variceal bleeding is the most common type of gastrointestinal bleeding in liver cirrhosis \[[@cit0028]--[@cit0030]\]. Variceal bleeding is primarily associated with the degree of portosystemic pressure gradient \[[@cit0031]\], rather than coagulation abnormalities or other abnormal factors \[[@cit0032]\]. Gastrointestinal endoscopy \[[@cit0031]\], but not other alternative diagnostic methods \[[@cit0033]--[@cit0035]\], is the diagnostic gold standard. Our study found that the presence of subcutaneous collateral vessel of the chest/abdominal wall was negatively associated with the probability of previous gastrointestinal bleeding or gastrointestinal bleeding upon admission. Such a significant association might be explained by the fact that subcutaneous collateral vessel of the chest/abdominal wall, a type of spontaneous portosytemic shunt, might produce a lower portosystemic pressure gradient, thereby decreasing the risk of variceal bleeding. However, we must acknowledge that only a proportion of our patients underwent endoscopic examinations for the diagnosis of gastroesophageal varices. Thus, in future, well-designed studies should be performed to explore the association between subcutaneous collateral vessel of the chest/abdominal wall and gastroesophageal varices or hepatic vein pressure gradient. On the other hand, in our study the association of spider nevus with the probability of gastrointestinal bleeding was obscure. A possible explanation is that spider nevus might reflect the severity of liver dysfunction and its associated disturbance of sex hormones, but not that of portal hypertension.

Both spider nevus and subcutaneous collateral vessel of the chest/abdominal wall were positively associated with the severity of liver dysfunction, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase, total bilirubin, Child-Pugh score, and MELD score. These findings were similar to those of previous research \[[@cit0004], [@cit0005]\]. To the best of our knowledge, no study has evaluated the impact of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall on the survival of patients with liver cirrhosis. We found that neither of them was associated with in-hospital mortality. However, subcutaneous collateral vessels of the chest/abdominal wall, rather than spider nevus, could significantly predict worse overall survival during the follow-up period. Considering that spider nevus and subcutaneous collateral vessel of the chest/abdominal wall are readily available at the physical examinations, they should be considered as routine markers of liver dysfunction and death in our clinical work.

Our study had limitations. First, numerous studies have shown high prevalence of spider nevus in children regardless of chronic liver diseases \[[@cit0036]--[@cit0038]\]. Because our patients were adults, rather than children or adolescents, we could not extrapolate from our findings to the pediatric population. Second, spider nevus is distributed all over the body. However, we only collected data regarding spider nevi and subcutaneous collateral vessels on the abdominal and chest walls, and not other body positions. Third, CT examinations might be more accurate and objective for identifying the number of subcutaneous collateral vessels of the chest/abdominal wall \[[@cit0015]\]. However, we only collected data regarding the presence of subcutaneous collateral vessel of the chest/abdominal wall on the basis of physical examinations, and not CT examinations.

In conclusion, based on the results of a prospective observational study, physical examinations regarding spider nevus and subcutaneous collateral vessel of the chest/abdominal wall should be carefully performed for early and accurate prognostic evaluation of liver cirrhosis.
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